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6KRUWUXQQLQJWLWOH³Ponatinib for treating acute lymphoblastic leukaemia: an ERG perspective´ 
Abstract 
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer (Incyte Corporation) of ponatinib (Inclusig®) to submit 
evidence of its clinical and cost-effectiveness for previously treated Philadelphia-chromosome-
positive acute lymphoblastic leukaemia (Ph+ ALL) and chronic myeloid leukaemia. This paper 
focusses on Ph+ ALL. The School of Health and Related Research Technology Appraisal Group at 
the University of Sheffield was commissioned to act as the independent Evidence Review Group 
(ERG). 7KLV DUWLFOH SUHVHQWV WKH FULWLFDO UHYLHZ RI WKH FRPSDQ\¶V VXEPLVVLRQ E\ WKH (5* DQG the 
outcome of the NICE guidance.  
7KHFOLQLFDOHIIHFWLYHQHVVHYLGHQFHLQWKHFRPSDQ\¶VVXEPLVVLRQwas derived from a phase II, single-
arm, open-label, non-comparative study. Given the lack of comparative evidence, a naïve indirect 
comparison was performed against re-induction chemotherapy comparing major cytogenetic response 
and complete remission. Best Supportive Care (BSC) was assumed to produce no disease response. 
Despite the limited evidence and potential for biases, this study demonstrated that ponatinib was 
likely to be an effective treatment for patients with Ph+ ALL.  
The company submitted a state transition model that analysed the incremental cost effectiveness of 
ponatinib versus re-induction therapy and BSC for the treatment of Ph+ ALL in patients whose 
disease is resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment 
with imatinib is not clinically appropriate, or who have the Threonine-315-Isoleucine mutation. This 
population was further subdivided into those who were suitable for allogeneic stem cell transplant 
(allo-SCT) and those who were not.  
 
7KH FRPSDQ\¶V revised economic evaluation, following the clarification process, estimated 
incremental cost-effectiveness ratios (ICERs) in those suitable for allo-SCT of £31,123 per quality-
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adjusted life year (QALY) gained for ponatinib compared with re-induction chemotherapy and 
£26,624 per QALY gained compared with BSC. For those for whom allo-SCT was unsuitable the 
company-estimated ICER compared with BSC was £33,954 per QALY gained. Following a critique 
of the model, the ERG undertook exploratory analyses which when combined produced a range in 
ICERs (due to uncertainty of the most appropriate overall survival function) of dominant (being less 
expensive and providing more QALYs) to £11,727 per QALY gained compared with re-induction 
chemotherapy and between £7892 and £31,696 per QALY gained compared with BSC for those in 
whom allo-SCT was suitable. For those where allo-SCT was not suitable the ERG estimated that 
ponatinib was dominant. During the consultation period the company agreed a revised patient access 
scheme (PAS) which reduced the ICER ranges to £7156 to £29,995 per QALY gained vs BSC, and to 
less than £5000 per QALY gained vs re-induction chemotherapy. In people for whom allo-SCT was 
unsuitable ponatinib dominated BSC. The NICE appraisal committee concluded that ponatinib is a 
cost-effective use of NHS resources in the considered population, subject to the company providing 
the agreed discount in the PAS.  
 
Key points for decision makers 
x There is uncertainty in the cost-effectiveness of ponatinib for treating Philadelphia 
chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) due to the main clinical 
evidence being derived from a non-comparative study meaning that naïve indirect 
comparisons were necessary. 
x In patients with Ph+ ALL who are unsuitable for allogeneic stem cell transplant the use of 
ponatinib rather than best supportive care is estimated to be less costly and provide more 
quality-adjusted life-years. 
x In patients with Ph+ ALL who are suitable for allogeneic stem cell transplant the use of 
ponatinib rather than re-induction chemotherapy or best supportive care is expected to 
provide more health but at a greater cost. The anticipated cost per quality adjusted life year 
gained is likely to be less than £30,000. 
 
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new single health technologies within a single indication, soon after 
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their UK market authorisation.[1] Within the STA process, the company provides NICE with a 
ZULWWHQVXEPLVVLRQDORQJVLGHDPDWKHPDWLFDOPRGHOWKDWVXPPDULVHVWKHFRPSDQ\¶VHVWLPDWHVRIWKH
clinical and cost effectiveness of the technology. This submission is reviewed by an external 
organisation independent of NICE (the Evidence Review Group [ERG]), which consults with clinical 
VSHFLDOLVWVDQGSURGXFHVDUHSRUW$IWHUFRQVLGHUDWLRQRIWKHFRPSDQ\¶VVXEPLVVLRQWKH(5*UHSRUW
and testimony from experts and other stakeholders, the NICE Appraisal Committee (AC) formulates 
preliminary guidance, the Appraisal Consultation Document (ACD), which indicates the initial 
decision of the AC regarding the recommendation (or not) of the technology. Stakeholders are then 
invited to comment on the submitted evidence and the ACD, after which a further ACD may be 
produced or a Final Appraisal Determination (FAD) issued, which is open to appeal. An ACD is not 
produced when the technology is recommended within its full marketing authorisation; in this case, a 
FAD is produced directly. 
 
This paper presents a summary of the ERG report[2] for the STA of ponatinib for the treatment of 
Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in patients whose 
disease is resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment 
with imatinib is not clinically appropriate, or who have the Threonine-315-Isoleucine (T315I) 
mutation. A summary of the subsequent development of the NICE guidance for the use of this 
technology in England is also provided. Full details of all relevant appraisal documents (including the 
appraisal scope, ERG report, company and consultee submissions, FAD and comments from 
consultees) can be found on the NICE website.[2]  
 
2. The Decision Problem 
ALL is a rare and rapidly progressing form of leukaemia characterised by the excess production of 
immature white blood cells, called lymphoblasts (sometimes referred to as blast cells). Eventually, 
this affects the production of normal blood cells which leads to a reduction in the numbers of red 
cells, white cells and platelets in the blood.[3] ALL represents about 20% of all leukaemias in adults 
and is the most common form of childhood leukaemia.[4-6] Approximately 25%[5, 7, 8] of adults 
with ALL have an acquired chromosomal abnormality (known as Ph+ disease) caused by reciprocal 
translocations between chromosomes 9 and 22. The presence of the Ph chromosome in adults 
increases with age.[4-6] and Ph+ ALL individuals typically have a worse prognosis than those 
without this abnormality.[9] 
Survival in adult patients with ALL is poor. The 5-year survival rate for those aged 25-64 years in 
England was 37.1% for those diagnosed in 2008 whereas for individuals over 65 years, 5-year 
survival was 12.7%.[10] 
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2.1 Current Treatment 
The management of patients with Ph+ ALL is complex and there is currently no NICE guidance or 
pathway of care for the treatment of adults with Ph+ ALL in England. In general, the treatment of Ph+ 
ALL varies according to age, general fitness and health at diagnosis and the results of cytogenetic 
testing.  
An allogeneic stem cell transplant (allo-SCT) is the only potentially curative treatment for Ph+ ALL; 
however, it is limited by patient suitability as well as the availability of suitable donors and is 
associated with a significant risk of morbidity and mortality.[11] The use of oral tyrosine kinase 
inhibitors (TKIs) has become an integral component of therapy for people with Ph+ ALL. Currently, 
three TKIs (imatinib,[12] dasatinib[13] and ponatinib[14]) have an EU marketing authorisation for the 
treatment of Ph+ ALL. Neither imatinib nor dasatinib for the treatment of adult Ph+ ALL have been 
appraised by NICE and the extent to which these TKIs are used in current clinical practice is 
unknown. Dasatinib[13] was available for the treatment of adults with Ph+ ALL with resistance or 
intolerance to prior therapy, including imatinib through the Cancer Drugs Fund until November 2015 
when it was removed from the Cancer Drugs Fund list.[15]  
 
3. The Independent ERG Review 
In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification 
RQVSHFLILFSRLQWVLQWKHFRPSDQ\¶VVXEPLVVLRQ (CS),[16] in response to which the company provided 
additional information. [16] 7KH (5* DOVR PRGLILHG WKH FRPSDQ\¶V GHFLVLRQ DQDO\WLF PRGHO WR
produce an ERG base case and to assess the impact of alternative parameter values and assumptions 
RQWKHPRGHOUHVXOWV7KHHYLGHQFHSUHVHQWHGLQWKHFRPSDQ\¶VVXEPLVVLRQDQGWKH(5*¶VUHYLHZRI
that evidence is summarised here. 
 
3.1 Clinical Evidence Provided by the Company 
Evidence was presented in the CS[16] relating to the clinical effectiveness of ponatinib in ALL. No 
randomised controlled trials (RCTs) relevant to the decision problem were identified from the 
systematic review of the literature. The company identified a Phase I dose finding study,[17, 18] 
which was not deemed entirely relevant to either the recommended dose or the licensed indication, 
and a Phase II study (PACE).[19-21] Therefore, PACE was considered the pivotal evidence. No 
ongoing studies of ponatinib in Ph+ ALL patients were identified.  
PACE was an industry-sponsored, single-arm, non-comparative, open-label, multicentre study 
(including five sites in the UK) designed to evaluate the effectiveness of oral ponatinib at a starting 
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dose of 45mg once daily, in 449 people (53% male; 78% Caucasian) with chronic phase chronic 
myeloid leukaemia (n=270), accelerated phase chronic myeloid leukaemia (n=85), blast phase chronic 
myeloid leukaemia (n=62) or Ph+ ALL (n=32) who were resistant or intolerant to either dasatinib or 
nilotinib, or who had the T315I mutation after any TKI therapy (as confirmed by direct 
sequencing).[7, 19, 22]  Study participants in the PACE study were heavily pre-treated with prior 
TKIs and conventional therapy: 37% (167/449) had received two TKIs out of a possible four 
(imatinib, dasatinib, nilotinib or bosutinib). This population comprised the target population in the 
FRPSDQ\¶V GHFLVLRQ SUREOHP IRU 3K $// UHIOHFWLQJ WKH DQWLFLSDWHG SODFH LQ WKHUDS\ RI SRQDWLQLE
after treatment failure with prior TKI therapy. The primary outcome measure for Ph+ ALL patients in 
the PACE study was major haematological response (MaHR), which included complete haematologic 
responses (CHR) and no evidence of leukaemia at 6 months. The summary of product characteristics 
posology recommends considering discontinuation of ponatinib if a complete haematologic response 
has not occurred by 3 months (90 days).[14] 
The average daily dose for those patients receiving ponatinib was 42.3mg per day. The study was 
started in September 2010 and with an estimated completion date of March 2017. Data to August 
2015 were provided within the company¶VVXEPLVVLRQ. 
 
In response to clarification,[16] the company provided updated data (approaching three years longer 
follow-up than in the pivotal paper[19]). However, the updated data were marked commercial-in-
confidence and cannot be presented in this paper. 
 
Among patients with Ph+ ALL (all lines, n=32 [data not reported separately by line of therapy]), 41% 
(95% CI: 24% to 59%) achieved an MaHR within the first 6 months (primary endpoint). The duration 
of response ranged from 2 to 14 months or more (median 3 months), and the estimated rate of a 
sustained response of at least 12 months was 8%. The median time to MaHR for responders was 2.9 
weeks (range: 1.6 to 24 weeks). Furthermore, major cytogenetic response (MCyR) was reached in 
47% of patients, and 38% had a complete cytogenetic response (CCyR). The median time to MCyR 
for responders was 1 month (range: 0.9 to 3.7 months), with an estimated 32% of responding patients 
maintaining this response for at least 12 months. In Ph+ ALL patients, the progression-free survival 
and overall survival at 12 months was estimated to be 7% (median 3 months) and 40% (median 8 
months), respectively.[19] In addition, overall survival at 36 months was estimated to be 16%.[20] 
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Among the subgroup of Ph+ ALL patients who had the T315I mutation (n=22, all lines),[19] 36% 
(95% CI: not reported) had an MaHR within the first 6 months. A total of 40% of patients with Ph+ 
ALL achieved MCyR and 32% reached CCyR (95% CI: not reported for either outcome).[19] The 
ERG believes that caution should be used in the interpretation of the T315I data because of the small 
population size and study design limitations. 
At the latest data cut for treatment discontinuation, 31 of 32 patients had stopped ponatinib treatment. 
Fifty-three percent of patients discontinued because of progression of disease, 16% had died and 12% 
discontinued because of lack of efficacy. At the last data-cut (November 2012) where safety data can 
be presented in this paper the following severe, or life-threatening, treatment-related adverse events 
were observed: neutropenia (12%); anaemia (12%), thrombocytopenia (6%) febrile neutropenia (6%), 
abdominal pain (6%) and increased lipase (6%). All other serious or life-threatening treatment-related 
adverse events occurred in 1 (3%) or fewer patients. 
 
3.2 Critique of the Clinical Evidence and Interpretation 
The systematic review process followed by the company was reasonably comprehensive. Despite 
minor limitations in the cRPSDQ\¶V VHDUFK VWUDWHJ\ WKH (5* was reasonably confident that all 
relevant published studies (RCTs and non-randomised/non-controlled evidence) of ponatinib were 
included in the CS, including data from ongoing studies.  
Based on the quality assessment tool for non-randomised studies,[23] the ERG considered the PACE 
study to be a well-reported and conducted single-arm study. However, single-arm studies are 
associated with an array of potential biases,[24] most importantly the ability to estimate a relative 
treatment effect compared to a concurrent control. 
The clinical advisor to the ERG considered MaHR to be a weak surrogate endpoint for patients with 
Ph+ ALL. Ideally, a better endpoint for bridging to transplant would be minimal residual disease 
levels in the bone marrow, which is a more stringent criterion. However, although response 
milestones for patients with Ph+ ALL have not been well established, treatment strategies usually 
involve achieving a MaHR with the aim of proceeding to allo-SCT, if feasible.  
 
The main uncertainties that exist surrounding the clinical evidence for ponatinib relate to the unbiased 
estimation of treatment effects, optimal dosing, and duration of treatment. Whilst the clinical advisor 
to the ERG considered that the PACE study population was reflective of the Ph+ ALL population in 
England it was noted that patients in the study had received nilotinib, which is not representative of 
NHS practice.  
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3.3 Cost-Effectiveness Evidence Provided by the Company 
The company submitted an economic model to assess the cost-effectiveness of ponatinib in Ph+ ALL 
from the perspective of the NHS and Personal Social Services over a lifetime horizon. Both benefits 
and costs were discounted at a rate of 3.5% per annum. The model employed a state transition 
approach, with three-monthly time cycles and includes a half-cycle correction. The model originally 
submitted was amended by the company following the clarification process; only the revised model is 
detailed here. The company had a PAS agreed which represents a simple discount, the value of which 
is commercial in confidence; during the appraisal process the company agreed a second PAS, with a 
larger discount. Only results incorporating the PAS are presented within this report. 
Having entered the model, a hypothetical patient could receive one of three interventions: (i) 
ponatinib; (ii) re-induction chemotherapy; or (iii) BSC. The characteristics of the hypothetical patients 
were based on those in the PACE study with 62.5% male and an initial age of 53 years.[19]  
The simulated patient pathway was identical for those patients receiving ponatinib or re-induction 
chemotherapy in that if an MyCR (for ponatinib) or complete remission (CR) (for re-induction 
chemotherapy) was achieved, the patient was assumed to receive allo-SCT (if suitable). The different 
response levels were chosen to align with the study data. Clinical advice provided to the ERG 
suggested that the results following an allo-SCT are better in those patients with minimal residual 
disease than those with greater disease levels at the time of transplant. For patients who received BSC, 
it was assumed that there would be no response (NR). For all treatments, death could occur at any 
time point.  
For patients who received ponatinib or re-induction chemotherapy, the model simulated the response 
of patients to the treatment, which was assumed to occur in the first cycle only. It was assumed that 
patients would fall into one of two mutually exclusive and exhaustive states: remission (which 
incorporated either MyCR (ponatinib) or CR (re-induction chemotherapy) and NR. For patients 
simulated to experience remission, the next event in the model (a term which has been used to identify 
the next event whilst excluding remaining in the same health state) would be allo-SCT, if appropriate. 
Following allo-SCT, the next event is death. For those who experienced NR, and/or who are 
unsuitable for allo-SCT, the next event is death. For patients who received BSC, the only event 
possible is death. 
The response rates assumed in the model for each treatment in Ph+ ALL are detailed in Table 1. Data 
for MCyR for ponatinib were taken from the PACE study,[19] whilst data on CR for re-induction 
therapy were taken from Tavernier et al.[25] No attempts were made by the company to account for 
differences in prognostic variables and treatment effect modifiers between PACE and external 
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comparator studies. The ERG commented that this is a naïve unadjusted indirect comparison and 
could be associated with a high risk of bias. Advice provided by the clinical advisor to the ERG 
indicated that MCyR is harder to achieve than CR: if this is correct, the relative effectiveness between 
ponatinib and re-induction chemotherapy would be unfavourable to ponatinib. 
 
Table 1: Assumed response rates for each treatment 
Treatment  MCyR / CR (%) NR (%) Source  
Ponatinib 46.88   53.12 PACE[19] 
Re-induction chemotherapy 37.04   62.96 Tavernier et al.[25]  
BSC   0.00 100.00 Assumption 
BSC, best supportive care; CR, complete response; MCyR, major cytogenetic response; NR, no 
response 
 
The treatment-emergent serious adverse events described earlier were incorporated in the model along 
with peripheral vascular events (5%) and venous thromboembolism events (4%). Adverse events were 
only assumed to occur with ponatinib, not with chemotherapy or BSC. 
After simulating the response rates associated with each treatment, many other parameters in the 
model were assumed independent of initial treatment. This is appropriate where pivotal studies are of 
relatively short duration, but the reliance on extrapolating from surrogate data increases the 
uncertainty in the results. The company used the Solver function in Microsoft Excel® to minimise the 
sum of squared errors (SSE) between the predicted survival function and that of the digitised points 
and, if the extrapolation was believed by the company to be clinically plausible, the survival function 
with the lowest SSE was selected. 
For patients who experienced remission (MyCR or CR) it is assumed that if a patient was suitable for 
allo-SCT then this would occur. The probability of death was conditional on whether a patient 
received allo-SCT, and whether the patient experienced remission or not. 
The probability of death following allo-SCT was derived from data presented in Tavernier et al.[25] 
Standard parametric models were undertaken using exponential, Weibull, Gompertz, log-normal and 
log-logistic survivor functions. All distributions pooled data from patients with MCyR and NR and 
used a covariate for response level. The data were digitised and survival functions fitted by 
minimising the SSE between the observed data-points and fitted survival function. With the exception 
of the exponential distribution, the range in SSE was relatively small (0.04 ± 0.05). The company 
selected the log-logistic distribution for use in the base case model. 
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The probability of death for those patients who experienced remission but were not suitable for allo-
SCT was estimated from data collected in the PACE study.[19] The company fitted standard 
paramtric models to these data. Based on these analyses the company stated that the best fit using the 
Akaike information criterion (AIC) and Bayesian information criteria (BIC) were not in agreement 
but of the two best fitting models for AIC and BIC the exponential distribution was selected as it was 
considered to be more clinically plausible than the Gompertz survival function (data were marked as 
academic-in-confidence). It was assumed that the probability of death was independent of whether 
ponatinib or re-induction chemotherapy provoked the remission. 
It was also assumed that the probability of death following NR would be the same following ponatinib 
or re-induction chemotherapy with these risks estimated from the PACE study,[19] using the survival 
analysis method described previously. The exponential survival function was selected as this was 
deemed by the company to be more clinically plausible than the Gompertz survival function For 
patients who received BSC the risk of death was estimated using data reported from an Italian single-
centre retrospective study in ALL patients.[26] This study reported a median overall survival of 2.6 
months and this value was used to fit an exponential function, although no justification for a constant 
hazard was provided. 
The duration of ponatinib treatment was estimated using individual patient data from the PACE 
study.[19] The company fitted standard parametric models to these data. Based on this analysis the 
company stated that the best fit using the AIC and BIC criteria was the log-logistic survival function 
(data were marked as academic-in-confidence). The duration of re-induction chemotherapy was a 
maximum of six-weeks.  Following cessation of ponatinib of re-induction chemotherapy it was 
assumed that BSC would be provided until death; where BSC was the first line treatment it was 
assumed to be continued until death. 
The company performed a systematic review to identify evidence regarding health related quality of 
life and assumed that the utilities reported by Szabo et al.[27] for blast phase chronic myeloid 
leukaemia were applicable for patients with Ph+ ALL. As such, those patients who responded to 
treatment were assumed to have a utility decrement of 0.286 and those patients who did not respond 
to treatment had a utility decrement of 0.556 compared with the general population.[28] Patients who 
received allo-SCT were assumed to have a utility decrement that reduced over time, being 0.296 
within the first three months,[29] 0.136 after six months[30] and assumed to be 0.216 between three 
and six months. The utilities for all adverse events were assumed to be 0.52 based on Szabo et al.[27] 
from which a utility decrement was estimated based on the estimated general population value.  
The cost of a six-week course of re-induction chemotherapy was assumed to be £18,000, based on 
British National Formulary data (reference not provided) and an assumption that Leucémie Aiguës 
/\PSKREODVWLTXH GH O¶$GXOWH (LALA-94), hyperfractionated cyclophosphamide, vincristine, 
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doxorubicin (adriamycin), dexamethasone and cytarabine and methotrexate (Hyper-CVAD) and 
fludarabine, cytarabine, methotrexate, granulocyte-colony stimulating factor, and idarubicin (FLAG-
IDA) were used equally. The cost of BSC was assumed to be £4064 based on Pagano et al.[26] The 
cost of ponatinib was stated to be commercial-in-confidence because of the PAS and the dosing 
regimens observed in PACE.[19]  
Based on a UK survey conducted by the company the number of days in hospital per cycle was 
assumed to be zero for those with a response and 26.64 for those with no response. Monitoring costs 
were assumed to be independent of treatment for the response and non-response states. The company 
assumed that patients with Ph+ ALL who responded to treatment would require the same monitoring 
resources as patients with chronic phase chronic myeloid leukaemia whilst those with Ph+ ALL who 
did not respond to treatment were assumed to require the same monitoring resources as patients with 
blast phase chronic myeloid leukaemia No additional costs of monitoring cardiovascular events were 
considered for ponatinib.. Hospitalisation and monitoring costs per cycle were estimated as £208 for 
responders and £24,070 for non-responders. The company assumed that the cost of allo-SCT was 
£60,092, based on data from the UK Stem Cell Strategy Oversight Committee.[31] The follow-up 
costs decreased over time, with a per cycle cost of: £12,215 in year 1; £3518 in year 2, and £420 in 
year 3. A cost of £5766 was assumed to be incurred at death based on a survey undertaken by the 
company. The components of each cost estimate were valued at 2014/15 prices unless a more recent 
value was available. 
Following the clarification period, the company estimated that the incremental cost-effectiveness ratio 
(ICER) for ponatinib to be £26,624 per QALY gained compared with BSC and was £31,123 per 
QALY gained compared with re-induction chemotherapy. Sensitivity analysis comparing ponatinib to 
re-induction chemotherapy showed that the ICER was very sensitive to the response rate generated by 
re-induction chemotherapy. For patients for whom allo-SCT was unsuitable, the company-estimated 
ICER was £33,954 per QALY gained for ponatinib compared with BSC. This ICER was most 
sensitive to the assumed response rate associated with ponatinib. Results from probabilistic sensitivity 
analyses were consistent with deterministic analyses. 
During the appraisal the company agreed an increased commercial-in-confidence discount and 
amended errors highlighted by the ERG. This resulted in base case ICERs estimated by the company 
of £26,319 per QALY gained compared with BSC and was £29,812 per QALY gained compared with 
re-induction chemotherapy for patients suitable for allo-SCT. The company-estimated ICER 
compared with BSC for those unsuitable for allo-SCT was £31,210 per QALY gained. 
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3.4 Critique of the cost-effectiveness evidence and additional work undertaken by the ERG 
The ERG made changes to the model / analyses presented by the company. These are detailed below. 
The ERG believed that the method used by the company in fitting survival functions to digitised 
survival data is inappropriate. The ERG had concerns with the approach used as this method weights 
points equally despite the number of patients contributing data to the curve declining as time 
progresses and provides no information about parameter uncertainty. A better approach would be to 
use the method presented by Guyot et al.[32] which allows estimation of parameters and their 
uncertainty.  
The ERG believed insufficient sensitivity analyses were undertaken by the company. Kass et al.[33] 
state that a difference in the BIC of less than two is barely worth a mention, whilst only difference 
values of six or greater indicate strong evidence that one survival function may be preferable to 
another. In addition, measures of goodness-of-fit of the models to the sample data such as the BIC 
does not take clinical plausibility of the extrapolated survival functions into account. Taking the BIC 
and clinical plausibility into consideration, the ERG undertook exploratory results using alternative 
survival functions to those selected by the company. Where multiple survival functions were thought 
SODXVLEOH WKHFRPSDQ\¶VEDVHFDVHZDVH[plored along with the survival function that had the most 
different predictions of long-term outcome to that produced by WKH FRPSDQ\¶V GHIDXOt survival 
function, to test extreme values. The survival functions considered to be potentially credible by the 
ERG and the clinical advisor to the ERG were: for overall survival following response to ponatinib 
treatment but not receiving allo-SCT, the exponential and the Gompertz distributions; for duration of 
ponatinib treatment, the log-normal and the log-logistic distributions; and for overall survival after 
allo-SCT, the Gompertz, the log-normal and the log-logistic distributions.  
The company had used two different sources in the model for non-responding patients assuming a 
median life expectancy of 5.57 months based on data from the PACE study.[19] For patients who 
received BSC, the median life expectancy was assumed to be 2.60 months, as reported by Pagano et 
al.[26] This difference in estimated survival for non-responders, which is based on a naïve indirect 
comparison, did not have face validity with the clinical advisor to the ERG. In the clarification 
response,[16] the company reported that the median age in Pagano et al.[26] was higher (77 years) 
compared with the median age in PACE (62 years) and that this could have caused the longer mean 
survival observed in PACE. The ERG amended the model to explore the impact of setting the survival 
following non-response equal for those who have ponatinib and those that have BSC, which was 
supported by clinical advice provided to the ERG.  
 
The ERG was concerned that the company assumption that unused tablets in a prescription would 
eventually be used was incorrect and an analysis was conducted assuming drug wastage. Due to the 
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construct of the model, prescriptions were assumed to occur at three-monthly intervals and this 
interval could not be altered by the ERG in the timelines of the STA. As such, the ICER was likely to 
be greater than were the true frequency of prescriptions, which is anticipated to be more frequent than 
three months, used. 
In addition to the errors identified by the ERG and corrected by the company, the intervention costs 
were half-cycle corrected by the manufacturer, and there was an implementation error that resulted in 
immortality for one cycle for a small subset of patients. These perceived errors were corrected by the 
ERG. The inclusion of treatment-related deaths was explored but was omitted from the ERG base 
case, which is likely to be favourable to ponatinib. 
The company provided no analyses for patients with the T315I mutation. If the presence of the 
mutation were known then re-induction chemotherapy would not be an option. If a person was known 
to not have the T315I mutation then the ICER compared with re-induction chemotherapy would likely 
be less favourable to ponatinib, although the extent of the increase is uncertain. 
 
The results of the ERG base case analyses are provided in Table 2 for patients suitable for allo-SCT 
and Table 3 for patients unsuitable for allo-SCT. 
 
Table 2: 7KHLPSDFWRIWKH(5*¶Vdeterministic exploratory analyses in patients suitable 
for allo-SCT 
 Cost per QALY (£) 
Ref No Exploratory Analyses Ponatinib vs re-induction 
chemotherapy 
Ponatinib vs BSC 
0 N/A (Company base case) 29,812 26,319 
1 Recalculation of the OS post allo-SCT curve  54,615 52,949 
2 Choosing alternative distributions in addition 
to those selected by the company, using the 
FRPSDQ\¶VILWVUDQJH 
22,840 ± 51,337 19,649 ± 31,577 
3 Assuming drug wastage 31,062 26,610 
4 No half-cycle correction of intervention costs 41,293 28,992 
5 Including treatment related deaths 26,739 25,524 
6 Removal of immortality for a small subset of 
patients 
30,523 26,653 
7a Setting OS the same for NR regardless of 
whether the patient had ponatinib or BSC ± set 
at the ponatinib value  
Dominant 12,661 
7b Setting OS the same for NR regardless of 
whether the patient had ponatinib or BSC ± set 
at the BSC value 
Dominant  18,690 
8 1, 3,4 and 6 using the curves believed most 
credible by the company 
84,570 61,273 
9 1, 3,4, 6 and 7a using the curves believed most 
credible by the company 
4138 29.995 
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10. ERG 
base 
case 
ICERs 
As 9, but choosing alternative distributions in 
addition to those selected by the company 
(range)  
 
Dominant ± 4138 7156 ± 29,995 
Allo-SCT, allogeneic stem cell transplant; BSC, best supportive care; ERG, Evidence Review Group; ICER, incremental cost-
effectiveness ratio; N/A, not applicable; NR, non-responders; OS, overall survival; QALY, quality-adjusted life year 
Note: the ICERs may be unfavourable to ponatinib as it is assumed that prescriptions are at three-monthly intervals when assessing drug 
wastage. 
 
Table 3: 7KHLPSDFWRIWKH(5*¶VGHWHUPLQLVWLFH[SORUDWRU\DQDO\VHVLQSDWLHQWV
unsuitable for allo-SCT 
 Cost per QALY (£) 
Ref No Exploratory Analyses Ponatinib vs BSC 
0 N/A (Company base case) 31,210 
1 Choosing alternative distributions in addition to those selected by the 
FRPSDQ\XVLQJWKHFRPSDQ\¶VILWVUDQJH 
24,790 ± 33,105 
2 Assuming drug wastage 33,826 
3 No half-cycle correction of intervention costs 44,031 
4 Including treatment related deaths 27,489 
5a Setting OS the same for NR regardless of whether the patient had 
ponatinib or BSC ± set at the ponatinib value  
Dominant 
5b Setting OS the same for NR regardless of whether the patient had 
ponatinib or BSC ± set at the BSC value 
Dominant  
6 2 and 3 using the curves believed most credible by the company 47,884 
7 2, 3, and 5a using the curves believed most credible by the company Dominant 
8. ERG 
base 
case 
ICERs 
As 7, but choosing alternative distributions in addition to those selected 
by the company (range)  
 
Dominant to Dominant 
BSC, best supportive care; ERG, Evidence Review Group; ICER, incremental cost-effectiveness ratio; N/A, not applicable; NR, non-
responders QALY, quality-adjusted life year 
Note: the ICERs may be unfavourable to ponatinib as it is assumed that prescriptions are at three-monthly intervals when assessing 
drug wastage. 
 
3.5 Conclusions of the ERG Report 
The key clinical effectiveness evidence for ponatinib was a single arm study recruiting 32 patients 
with Ph+ ALL. Naïve indirect comparisons were used to compare ponatinib against re-induction 
chemotherapy and BSC which are biased. The changes made by the ERG, and the company following 
the clarification process, along with a larger PAS resulted in the ICER estimated by the ERG to be 
between per QALY gained and £29,995 per QALY gained compared with BSC in patients suitable for 
allo-SCT. For patients unsuitable for allo-SCT, ponatinib was assumed to dominate (that is be less 
costly and more beneficial) than BSC. 
 
4. Key Methodological Issues 
Analyses conducted based on naïve indirect comparisons are biased. The face validity of each 
comparison should be carefully assessed. In the company submission, the expected survival for 
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patients who had no response from ponatinib, or re-induction chemotherapy, was assumed to be 
longer than patients on BSC, who were assumed to have no response. This assumption was not 
supported by the clinical advisor to the ERG. When the survival functions were set equal, the ICER 
changed markedly, in favour of ponatinib. 
The exploration of the impact of using alternative, plausible survival functions on the ICER was not 
undertaken by the company. The analyses undertaken by the ERG indicates that the range of the ICER 
was large and that a decision based on an ICER from a single survival function could be misleading. 
 
5. National Institute for Health and Care Excellence Guidance  
In June 2017, on the basis of the evidence available (including verbal testimony of invited clinical 
experts and patient representatives), the NICE appraisal committee (AC) produced guidance that 
ponatinib was recommended as an option for treating Ph+ ALL when the disease is resistant to 
dasatinib, or when the patient cannot tolerate dasatinib and for whom subsequent treatment with 
imatinib is not clinically appropriate, or the T315I gene is present and when the company provides the 
drug with the agreed PAS. 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination (FAD) 
This section summarises the key issues considered by the AC. The full list of the issues considered by 
the AC can be found in the FAD.[34]   
 
5.1.1 Uncertainties in the Clinical evidence 
The AC noted the lack of a comparator in the PACE study,[19] which was justified by the company 
on the basis that it was unethical to randomise patients to placebo or ponatinib in addition to best 
supportive care who have not responded to previous treatment. The AC was aware that for some 
patients in the study, the dosage was changed or treatment was stopped which led to uncertainties 
about the best dosing level, the duration of treatment, and the generalisability of the response rates. 
The AC also noted the small number of patients with Ph+ ALL in the PACE study. The committee 
concluded that despite these uncertainties the evidence presented was sufficient for decision making. 
 
5.1.2 Uncertainties in the Economic Modelling  
The AC noted that the company had µdone indirect comparisons because of a lack of direct 
comparative evidence¶. Nevertheless, the AC concluded that there was sufficient evidence for its 
decision-making. The AC considered the range of ICERs presented by the ERG. The AC understood 
that survival time following non-response was independent of treatment and concluded that the 
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sensitivity analyses undertaken by the ERG accounted for this uncertainty. The AC concluded that 
there was uncertainty about which parametric distributions were most plausible and clinically 
appropriate.  
 
5.1.3 End of Life Criteria 
The AC concluded that the end of life criteria (a survival of less than 2 years and an extension of life 
of more than 3 months) had been met for all patients with Ph+ ALL regardless of suitability for allo-
SCT. 
 
6. Conclusions 
The AC recognised that there was considerable uncertainty in the value of the ICERs, and therefore 
their most likely value fell within a range. The AC concluded that in all instances this range included 
cost-effective values, and therefore ponatinib was a cost-effective use of NHS resources.  
 
Acknowledgements 
This summary of the ERG report was compiled after NICE issued the FAD. All authors have 
commented on the submitted manuscript and have given their approval for the final version to be 
published. The views and opinions expressed therein are those of the authors and do not necessarily 
reflect those of NICE or the Department of Health. Any errors are the responsibility of the authors. 
Author contributions  
Matt Stevenson and Andrew Rawdin critiqued the mathematical model provided and the cost-
effectiveness analyses submitted by the company. Abdullah Pandor and Marrissa Martyn-St James 
critiqued the clinical effectiveness data reported by the company. Jean Hamilton and John Stevens 
critiqued the statistical aspects of the submission and the analyses performed by the company. Ruth 
Wong critiqued the literature searches undertaken by the company. Clare Rowntree provided clinical 
advice to the ERG throughout the project. All authors were involved in drafting and commenting on 
the final document. Matt Stevenson acts as the guarantor of the manuscript. This summary has not 
been externally reviewed by PharmacoEconomics. 
Compliance with Ethical Standards 
Funding 
This project was funded by the National Institute for Health Research (NIHR) Health Technology 
Assessment Programme (Project Number 16/51/11). Visit the HTA programme website for further 
project information (http://www.hta.ac.uk). 
Conflicts of Interest 
16 
 
Dr Clare Rowntree undertook some consulting work in 2015-16 for ARIAD Pharmaceuticals, the 
manufacturer of ponatinib. This work resulted in an authored published abstract in a health economics 
journal. MS, AP, JH, JS, MMSJ, AR, RW have no conflicts of interest to declare.  
17 
 
References 
1.  National Institute for Health and Care Excellence (NICE). Guide to the methods of technology 
appraisal 2013 - Process and methods [PMG9]. London: NICE. 2013. 
https://www.nice.org.uk/article/pmg9/. Accessed 23 November 2016. 
2.  Pandor A, Stevenson M, Martyn-St James M, Stevens J, Hamilton J, Rawdin A et al. Ponatinib 
for treating acute lymphoblastic leukaemia: A Single Technology Appraisal. School of Health 
and Related Research (ScHARR). 2016. 
https://www.nice.org.uk/guidance/ta451/documents/committee-papers. Accessed 20 November 
2017.  
3.  National Institute for Health and Care Excellence. Ponatinib for treating chronic myeloid 
leukaemia and acute lymphoblastic leukaemia. Final Scope. National Institute for Health and 
Care Excellence (NICE), London. 2016. 
https://www.nice.org.uk/guidance/ta451/documents/committee-papers. Accessed 20 November 
2017. 
4.  Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W et al. Acute lymphoblastic 
leukemia. J Natl Compr Canc Netw. 2012;10(7):858-914.  
5.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: 
Chronic Myelogenous Leukemia. Version 1.0. 2016. 
https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 23 November 
2016. 
6.  Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol 
Clin North Am. 2001;15(1):21-36.  
7.  European Medicines Agency (EMA). Assessment Report for Inclusig® (ponatinib). Procedure 
No EMEA/H/C/002695/0000. London: EMA. 2013. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Public_assessment_report/human/002695/WC500145648.pdf. Accessed 23 November 2017. 
8.  Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al. Outcome of 609 
adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 
study. Blood. 2007;109(3):944-50.  
9.  Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic 
leukemia. Hematology Am Soc Hematol Educ Program 2011:231-7.  
10.  Public Health England. National Cancer Intelligence Network Trends in incidence and outcome 
for haematological cancers in England: 2001-2010.  London: Public Health England. 2015. 
http://www.ncin.org.uk/view?rid=2818 Accessed 20 November 2017.  
11.  Ravandi F. Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 
Role of Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 2011;11(2):198-203.  
18 
 
12.  Novartis Europharm Limited. Glivec® (imatinib) 50-mg and 100-mg hard capsules and 100-mg 
and 400-mg film-coated tablets: Summary of Product Characteristics. [updated 28 November 
2016]. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000406/WC500022207.pdf Accessed 1 December 2016.  
13.  Bristol-Myers Squibb Pharma. Sprycel® (dasatinib) 20-mg, 50-mg, 70-mg, 80-mg, 100-mg, 
140-mg film-coated tablets: Summary of Product Characteristics. [updated 20 July 2016]. 2016. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000709/WC500056998.pdf Accessed 1 December 2016.  
14.  ARIAD Pharma Ltd. Iclusig® (ponatinib) 15-mg, 30-mg, and 45-mg film-coated tablets: 
Summary of Product Characteristics. [updated 16 September 2016]. 2016. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002695/WC500145646.pdf Accessed 1 December 2016.  
15.  Adcock A, Powell T. Removal of drugs from Cancer Drugs Fund list. London: House of 
Commons Library. 2016. 
http://researchbriefings.parliament.uk/ResearchBriefing/Summary/CDP-2016-0009. Accessed 1 
December 2016. 
16.  Incyte Corporation. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic 
leukaemia[ID671]. Response to Clarification Letter. 2016. 
https://www.nice.org.uk/guidance/ta451/documents/committee-papers Accessed 22 November 
2017. 
17.  Cortes  JE, Kantarjian  H, Shah  NP, Bixby  D, Mauro  MJ, Flinn  I et al. Ponatinib in 
Refractory Philadelphia Chromosome±Positive Leukemias. New England Journal of Medicine. 
2012;367(22):2075-88. doi:doi:10.1056/NEJMoa1205127. 
18.  Talpaz M, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn I et al. Four-year minimum 
follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in 
a phase 1 trial of ponatinib (PON). J Clin Oncol (Meeting Abstracts). 2015;33(15_suppl):7047.  
19.  Cortes  JE, Kim  D-W, Pinilla-Ibarz  J, le Coutre  P, Paquette  R, Chuah  C et al. A Phase 2 
Trial of Ponatinib in Philadelphia Chromosome±Positive Leukemias. New England Journal of 
Medicine. 2013;369(19):1783-96. doi:doi:10.1056/NEJMoa1306494. 
20.  Cortes  JE, Kim  D-W, Pinilla-Ibarz  J, le Coutre  P, Paquette  R, Chuah  C et al. Ponatinib 
Efficacy and Safety In Heavily Pretreated Leukemia Patients: 3-Year Results of the Pace Trial. 
P234. Haematologica. 2015;100(S1):64.  
21.  Hochhaus A, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R et al. Efficacy and 
Safety of Ponatinib in CP-CML Patients by Number of Prior Tyrosine Kinase Inhibitors: 4-
Year Follow-up of the Phase 2 PACE Trial. Blood. 2015;126(23):4025.  
22.  U.S. Food and Drug Administration Center for Drug Evaluation and Research. Application 
number: 203469Orig1s000 Medical review. 2012. 
19 
 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000MedR.pdf. 
Accessed 23 November 2016. 
23.  Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case 
series should be considered in systematic reviews of rapidly developing technologies. Journal 
of Clinical Epidemiology. 2009;62(12):1253-60. doi:10.1016/j.jclinepi.2008.12.010. 
24.  Evans S. Clinical trial structures. J Exp Stroke Transl Med. 2010;3(1):8-18.  
25.  Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T et al. Outcome of 
treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the 
LALA-94 trial. Leukemia. 2007;21(9):1907-14. doi:10.1038/sj.leu.2404824. 
26.  Pagano L, Mele L, Casorelli I, Fianchi L, Di Febo A, Leone G. Acute lymphoblastic leukemia 
in the elderly. A twelve-year retrospective, single center study. Haematologica. 
2000;85(12):1327-9.  
27.  Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state 
preference values associated with chronic myelogenous leukemia. Value in health : the journal 
of the International Society for Pharmacoeconomics and Outcomes Research. 2010;13(1):103-
11. doi:10.1111/j.1524-4733.2009.00573.x. 
28.  Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 1999. 
http://EconPapers.repec.org/RePEc:chy:respap:172chedp Accessed 1 December 2016. 
29.  van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and 
quality of life assessment comparing patients undergoing autologous peripheral blood stem cell 
transplantation or autologous bone marrow transplantation for refractory or relapsed non-
Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial. European Journal of 
Cancer (Oxford, England : 1990). 2001;37(14):1781-9.  
30.  Loveman E, Cooper K, Bryant J, Colquitt JL, Frampton GK, Clegg A. Dasatinib, high-dose 
imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a 
systematic review and economic evaluation. Health Technology Assessment (Winchester, 
England). 2012;16(23):iii-xiii, 1-137. doi:10.3310/hta16230. 
31.  UK Stem Cell Strategy Oversight Committee. NHS Blood and Transplant. Unrelated Donor 
Stem Cell Transplantation in the UK. Effective Affordable Sustainable. 2014. 
http://www.nhsbt.nhs.uk/download/unrelated_donor_stem_cell_transplantation_in_the_uk.pdf. 
Accessed 1 December 2016. 
32.  Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: 
reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research 
Methodology. 2012;12:9. doi:10.1186/1471-2288-12-9. 
33.  Kass RE, Raftery AE. "Bayes Factors",. Journal of the American Statistical Association. 
1995;90(430):773-95. doi:doi:10.2307/2291091. 
20 
 
34.  National Institute for Health and Care Excellence (NICE). Ponatinib for treating chronic 
myeloid leukaemia and acute lymphoblastic leukaemia - Technology appraisal guidance 
[TA451]. NICE, London. 2017. https://www.nice.org.uk/guidance/ta451/ Accessed 23 
November 2017. 
 
